Anondita Medi. moves to reshape its capital structure

Verdict

The reported IPO prospectus disclosures for Anondita Medicare Limited outline total net issue objects of Rs 61.16 Crores ^[1] (rather than INR 109.78 Crores). The allocation is heavily weighted toward operating scale, directing 57.2% (Rs 35.00 Crores) ^[1] into working capital requirements and 9.8% (Rs 6.00 Crores) ^[1] into plant machinery CapEx.

This capital allocation directly addresses the working capital pressure created by a 65.6% YoY top-line expansion in FY25 ^[1]. However, 0% of issue proceeds are allocated to direct debt reduction ^[1], leaving debt service dependent on operating cash flows while relying on equity base expansion to passively lower the Debt-to-Equity ratio from its FY25 level of 0.70x ^[1].

---

Objects of the Issue Allocation

The reported utilization of net IPO proceeds is broken down as follows:

• Notes: † Allocation percentages are derived from individual objects over total reported issue objects of Rs 61.16 Crores ^[1].*

---

Alignment with Audited Financials

1. Debt-to-Equity Ratio & Financial Leverage

• Current Leverage Baseline: As of the audited financial results for the year ended March 31, 2025, total debt stood at Rs 27.39 Crores ^[2] against a Net Worth of Rs 37.87 Crores ^[1], resulting in a reported Debt-to-Equity ratio of 0.70x ^[1].
• Historical Trajectory: The company has sequentially reduced leverage from 2.61x in FY23, 2.27x in FY24, and 1.53x as of June 30, 2024 ^[3].
• Capital Allocation Alignment: No issue proceeds are designated for debt prepayment or repayment ^[1]. The allocation relies entirely on expanding the post-issue equity denominator to lower the net leverage ratio passively.
• Subsequent Liability Structure: In Q2 FY26, non-current liabilities were reported at Rs 134.66 Crores ^[4].

2. Working Capital Requirements

• Operational Scale Growth: Total income increased by 65.6% YoY to Rs 77.13 Crores in FY25 from Rs 46.56 Crores in FY24 ^[1], while PAT expanded to Rs 16.42 Crores ^[1].
• Balance Sheet Absorption: As of March 31, 2025, current assets stood at Rs 40.57 Crores ^[2] against current liabilities of Rs 23.62 Crores ^[2], yielding a net working capital of Rs 16.95 Crores (derived from current assets of Rs 40.57 Crores ^[2] less current liabilities of Rs 23.62 Crores ^[2]).
• Capital Allocation Alignment: The Rs 35.00 Crore equity allocation for working capital ^[1] represents more than double the existing net working capital base (Rs 16.95 Crores). This capital injection directly funds working capital cycles, supporting historical trade receivables turnover (3.72x in FY24 ^[3]) and inventory turnover (4.40x in FY24 ^[3]).
• Working Capital Stress: Subsequent reporting in Q2 FY26 shows consolidated current liabilities of Rs 1,447.5 Crores ^[5] and a Q3 FY26 consolidated current ratio of 0.37x ^[6], highlighting high working capital intensity and confirming why working capital dominates the issue allocation.

---

Analyst Take & Limitations

• Proceeds Discrepancy Note: The prospectus disclosures cite total net issue objects of Rs 61.16 Crores ^[1]; an issue proceeds figure of INR 109.78 Crores is not reflected in the reported objects table.
• Acquisition Risk: With 33.0% (Rs 20.16 Crores) earmarked for "Unidentified Acquisition and General Corporate Purposes" ^[1], deployment details remain uncommitted, introducing allocation discipline risk.
• Deleveraging Dependence: Because debt repayment is omitted from the issue objects ^[1], overall solvency depends on maintaining high operating margins (EBITDA margin was 33.32% in FY25 ^[1]) to service existing interest obligations.*

The available filings and news disclosures do not report a confirmed rights issue or an entitlement ratio for Anondita Medicare. Instead, the corporate action disclosed in recent news is a preferential issue of convertible warrants to promoters ^[7].

Preferential Warrant Terms vs. Rights Issue

• Reported Action: In-principle NSE approval for the preferential issuance of 2,85,000 convertible equity share warrants to the promoter category ^[7].
• Issue Price: Rs 1,038 per warrant (face value Rs 10) ^[7].
• Entitlement Ratio: Not applicable and not reported, as this is a preferential allotment of warrants rather than a proportional rights entitlement to existing shareholders ^[7].

Comparison to Book Value Per Share

• Book Value Per Share (BVPS): Derived at approximately Rs 20.40 per share, based on Total Equity of Rs 180.88 Crores ^[8] and Equity Share Capital of Rs 88.64 Crores ^[9], assuming a face value of Rs 10 per share ^[7].
• Valuation Context: The preferential warrant issue price of Rs 1,038 per share ^[7] is priced at a substantial premium over the company's book value per share.

Comparison to Recent Trading Levels and Volume

• Trading Price: The stock closed at Rs 1,088.75 on July 31, 2026, trading within a 3-month range of Rs 929.65 to Rs 1,233.15 (``). The warrant issue price of Rs 1,038 <sup>[7]</sup> reflects a narrow discount to prevailing market prices.
• Trading Volume: Specific share trading volume data is not reported in the available dataset, as only daily closing prices and percentage returns are provided (``).

Capital Raise vs. Operating Cash Flow Baseline

Anondita Medicare Limited has not reported three-year historical Cash Flow from Operations (CFO) or Free Cash Flow (FCF) data in company filings. Consequently, a direct historical comparison between the cited INR 109.78 crore capital raise and multi-year organic cash generation cannot be established from reported disclosures.

From reported balance sheet metrics, an INR 109.78 crore capital influx compares to the company's Q2 FY26 liability base as follows:

• Notes: † Derived sum of current liabilities (Rs 1,447.50 Crores) ^[5] and non-current liabilities (Rs 134.66 Crores) ^[4].*

---

Strategic Direction: Debt Reduction vs. Capacity Expansion

• Expansion Focus: Company filings indicate an operational thrust toward expanding international healthcare and institutional supply opportunities across both Male and Female condom manufacturing categories ^[10].
• Liability Profile: Given that current liabilities (Rs 1,447.50 Crores ^[5]) substantially outweigh non-current liabilities (Rs 134.66 Crores ^[4]), capital deployment would logically need to balance short-term working capital requirements against capex needed for international market expansion ^[10].
• Use of Proceeds Breakdown: Specific offer object allocations (exact percentage split between debt paydown, civil/machinery capex, and working capital) for the INR 109.78 crore raise are not reported in Anondita's available disclosures.

---

Analytical Limitations

• Historical Cash Flow Gap: FY23, FY24, and FY25 cash flow statements (CFO, CFI, CFF, and calculated FCF) for Anondita Medicare Limited have not been published in available disclosures.
• Cross-Entity Information: Secondary market disclosures in the retrieved context contain issue usage details for an unrelated entity (Bio Medica Laboratories Limited, which allocated proceeds toward civil construction, plant & machinery, and Rs 6.50 Crores of debt repayment ^[11]); these figures do not belong to Anondita Medicare Limited and cannot be used as a proxy.*